Compare XRX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | VNDA |
|---|---|---|
| Founded | 1906 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 361.4M |
| IPO Year | 2019 | 2005 |
| Metric | XRX | VNDA |
|---|---|---|
| Price | $2.74 | $5.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.50 | ★ $14.90 |
| AVG Volume (30 Days) | ★ 3.5M | 858.1K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ 23.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $117,000,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $8.96 | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.19 | $4.14 |
| 52 Week High | $6.80 | $9.91 |
| Indicator | XRX | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 35.47 |
| Support Level | $2.40 | $5.11 |
| Resistance Level | $2.89 | $5.58 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 19.20 | 11.99 |
Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.